Asthma – US Drug Forecast and Market Analysis to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Asthma – US Drug Forecast and Market Analysis to 2023 in subject line and your contact details. Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as shortacting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting betaagonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline. The 2013 base-year market sales for asthma pharmaceuticals in the US were around $10.1 billion. As in the global market, this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as the patent expiry of numerous SABA, ICS, and ICS/LABA products over the forecast period, will be offset by eight pipeline product launches, seven of which are targeted biologics. Complete report available at http://www.marketoptimizer.org/asthma-us-drug-forecast-and-marketanalysis-to-2023.html . Scope Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in the US from 2013-2023. Analysis of the impact of key events as well the drivers and restraints affecting the US Asthma market. Reasons to Buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Asthma. Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2013-2023 in US.
Inquire for discount @ http://www.marketoptimizer.org/contacts/discount?rname=10535 (Report price: Single user license- US$ 4995 ) Table of Contents Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Prognosis 3.1.4 Quality of Life 3.2 Symptoms 4 Disease Management 4.1 Diagnosis and Treatment Overview Buy a Copy of the Report @ http://www.marketoptimizer.org/contacts/purchase?rname=10535 . Table of Contents 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment
5.3 Inhaled Corticosteroids 5.3.1 Flovent (fluticasone propionate) 5.3.2 Pulmicort (Budesonide) 5.3.3 Other Inhaled Corticosteroids 5.4 Long-Acting Beta-Agonists 5.4.1 Overview 5.5 Inhaled Corticosteroids/Long-Acting Beta-Agonists 5.5.1 Advair (fluticasone propionate/salmeterol xinafoate) 5.5.2 Symbicort (Budesonide/formoterol fumarate) 5.5.3 Breo Ellipta (fluticasone furoate/vilanterol trifenatate) 5.5.4 Dulera (mometasone furoate/formoterol fumarate) 5.6 Leukotriene Modifiers 5.6.1 Singulair (montelukast) Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Asthma – US Drug Forecast and Market Analysis to 2023� report OR for any other market research and intelligence needs you may have for your business.